Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoquercetin + aspirin is a combination of two agents with antiplatelet and antithrombotic properties. Isoquercetin (also known as quercetin-3-O-glucoside) is a flavonoid glycoside derived from quercetin, found in various fruits and vegetables. It exhibits anticoagulant effects by inhibiting protein disulfide isomerase activity, reducing platelet aggregation, and attenuating blood coagulation[3][5]. Aspirin (acetylsalicylic acid) irreversibly inhibits cyclooxygenase-1 (COX-1), thereby suppressing thromboxane A2 production and inhibiting platelet activation. Studies have shown that isoquercetin or its metabolites can synergistically enhance the antiplatelet effects of aspirin more-than-additively[2][6], suggesting potential for improved prevention of thrombosis or cardiovascular events when used together. This combination has been investigated for conditions such as pre-eclampsia[1], sickle cell disease-related thromboinflammation[5], and general thrombosis risk reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isoquercetin + aspirin.